ENDPOINTS

Post-Hoc: AI bio needs to heed the overhyped history of CRISPR

John Evans can now reminisce about the days of unrealistic expectations. As CEO of the gene editing biotech Beam Therapeutics, Evans remembers when CRISPR buzz was at its apex, fielding questions at investor conferences on ...

May 22, 2025 - 12:04
 0
Post-Hoc: AI bio needs to heed the overhyped history of CRISPR
John Evans can now reminisce about the days of unrealistic expectations. As CEO of the gene editing biotech Beam Therapeutics, Evans remembers when CRISPR buzz was at its apex, fielding questions at investor conferences on ...
Read More

Tags:

Previous Article

Boost your workflow for life with this $60 AI assistant

Next Article

New Tobii Partnership Paves the Way for Next-gen Eye-tracking Tech in XR Headsets

Related Posts

FDA adcomm votes unanimously against Pfizer's prostate cancer drug combo

FDA adcomm votes unanimously against Pfizer's prostate ...

May 22, 2025  0

Republican tax cut bill includes PBM, drug price negotiation changes

Republican tax cut bill includes PBM, drug price negoti...

May 12, 2025  0

Amarin urges Supreme Court to decline Hikma's drug label spat

Amarin urges Supreme Court to decline Hikma's drug labe...

May 16, 2025  0